DS
TARS icon

David Shaw’s Tarsus Pharmaceuticals TARS Stock Holding History

David Shaw’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.7M Sell
710,559
-80,587
-10% -$5.15M 0.02% 814
2026
Q1 		$55.5M Buy
791,146
+175,990
+29% +$12.3M 0.03% 613
2025
Q4 		$50.4M Buy
615,156
+16,849
+3% +$1.26M 0.03% 698
2025
Q3 		$35.6M Sell
598,307
-124,876
-17% -$6.15M 0.02% 831
2025
Q2 		$29.3M Buy
723,183
+312,507
+76% +$14.1M 0.02% 822
2025
Q1 		$21.1M Buy
410,676
+45,132
+12% +$2.23M 0.02% 915
2024
Q4 		$20.2M Buy
365,544
+183,449
+101% +$8.33M 0.01% 1027
2024
Q3 		$5.99M Sell
182,095
-87,698
-33% -$2.46M 0.01% 1798
2024
Q2 		$7.33M Buy
269,793
+73,281
+37% +$2.46M 0.01% 1562
2024
Q1 		$7.14M Buy
196,512
+155,985
+385% +$4.59M 0.01% 1629
2023
Q4 		$821K Buy
+40,527
New +$677K ﹤0.01% 3266
2023
Q3 		– Sell
-23,451
Closed -$424K – 4489
2023
Q2 		$424K Buy
23,451
+5,884
+33% +$93.5K ﹤0.01% 3484
2023
Q1 		$221K Buy
+17,567
New +$257K ﹤0.01% 3865

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

David Shaw's TARS Position: Q2 2026 in Review

David Shaw reduced its Tarsus Pharmaceuticals (TARS) stake by 10% in Q2 2026, selling an estimated $5.15M and leaving 710,559 shares worth $44.7M. The position accounts for 0.02% of the portfolio, ranked #814.

David Shaw first reported a position in TARS in Q1 2023 and has held it in 13 quarters since. The position peaked at $55.5M in Q1 2026. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • David Shaw held 710,559 shares of Tarsus Pharmaceuticals worth $44.7M as of Q2 2026.
  • David Shaw sold 80,587 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $5.15M.
  • Tarsus Pharmaceuticals made up 0.02% of David Shaw's portfolio in Q2 2026, its #814 holding.
  • David Shaw first reported a position in Tarsus Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • David Shaw's Tarsus Pharmaceuticals position peaked at $55.5M in Q1 2026.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.